Theriva Biologics Reports VCN-01 Phase 1 Trial Results: Improved Survival and Immune Response in Refractory Head & Neck Cancer 12
Theriva Biologics Reports Positive Results from VCN-01 Phase...
Sign in to continue:
Theriva Biologics Reports Positive Results from VCN-01 Phase...
ZincFive to Go Public via \$752M SPAC Deal with Spark I Acqu...
Nakamoto Inc. Announces Major Debt Reduction, Refinancing, a...
Coupang, Inc. 8-K Filing: Key Details and Investor Implicati...
NXP Semiconductors N.V. Announces Key Results from 2026 Annu...
McGraw Hill, Inc. 2026 Annual Report - Investor Highlights ...
Top Glove Corporation Bhd: Notification of Q3 2026 Results R...
Oasis Harvest Corporation Berhad: Major Corporate Proposals ...
PUC Berhad Proposes RM350 Million Share Capital Reduction ...
Pentech Holdings Berhad - Detailed First Quarter Financial R...